Skip to main content
Contact Us
Subscribe
E-Edition
31°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.060
-0.030 (-2.75%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
February 23, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
February 23, 2023
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
Via
News Direct
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
February 23, 2023
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...
Via
Benzinga
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board
February 23, 2023
World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Files US IND Application For Dry Eye Disease Candidate
November 21, 2022
Via
Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 21, 2023
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 21, 2023
Via
Benzinga
Nasdaq Drops Over 100 Points; Walmart Issues Cautious Forecast
February 21, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. Following the market opening Tuesday, The Dow traded down 1.15% to 33,438.86 while the NASDAQ...
Via
Benzinga
BABA Stock Alert: What to Know as Ant Group Teams Up With China’s NBA League
February 21, 2023
Alibaba (BABA) stock is a hot topic on Tuesday as investors react to news of Ant Group teaming up with China's NBA league.
Via
InvestorPlace
Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
February 21, 2023
OKYO Pharma (OKYO) stock is falling on Tuesday following a recent rally as the company prepares for a presentation this week.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 21, 2023
Via
Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
February 21, 2023
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 21, 2023
It's time to start another day of trading with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!
Via
InvestorPlace
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
February 21, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
February 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 31, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 16, 2023
Via
Benzinga
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022
December 30, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
December 22, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO to Participate at Biotech Showcase
December 21, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC
December 06, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited - Change of Auditor
December 01, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited – PDMR dealing
November 24, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
November 21, 2022
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 10, 2022
Gainers NexImmune (NASDAQ:NEXI) shares rose 38.8% to $0.7 during Thursday's pre-market session. The market value of their outstanding shares is at $16.9 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.